MASATAKA SUZUKI

TitleAssistant Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Medicine
Address1102 BATES
Houston, TX 77030
vCardDownload vCard
    Other Positions
    TitleAssistant Professor
    InstitutionBaylor College of Medicine
    DepartmentCenter for Cell & Gene Therapy
    DivisionCenter for Cell & Gene Therapy


    Collapse Research 
    Collapse research activities and funding
    R00HL098692     (SUZUKI, MASATAKA)Jan 10, 2013 - Nov 30, 2016
    NIH
    Blocking the immune response to HDAd for Hemophilia A gene therapy
    Role: Principal Investigator

    K99HL098692     (SUZUKI, MASATAKA)Aug 9, 2010 - Nov 30, 2012
    NIH
    Blocking the immune response to Helper-dependent adenovirus vector for Hemophilia
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Rosewell Shaw A, Porter C, Biegert G, Jatta L, Suzuki M. HydrAd: A Helper-Dependent Adenovirus Targeting Multiple Immune Pathways for Cancer Immunotherapy. Cancers (Basel). 2022 Jun 02; 14(11). PMID: 35681750.
      Citations:    
    2. Biegert GWG, Rosewell Shaw A, Suzuki M. Current development in adenoviral vectors for cancer immunotherapy. Mol Ther Oncolytics. 2021 Dec 17; 23:571-581. PMID: 34938857.
      Citations: 2     
    3. McKenna MK, Englisch A, Brenner B, Smith T, Hoyos V, Suzuki M, Brenner MK. Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity. Mol Ther. 2021 Dec 01; 29(12):3529-3533. PMID: 34706248.
      Citations: 1     Fields:    
    4. Rosewell Shaw A, Porter CE, Yip T, Mah WC, McKenna MK, Dysthe M, Jung Y, Parihar R, Brenner MK, Suzuki M. Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors. Commun Biol. 2021 03 19; 4(1):368. PMID: 33742099.
      Citations: 7     Translation:HumansCells
    5. Warren EAK, Anil J, Castro PD, Kemnade J, Suzuki M, Hegde M, Hicks J, Yu W, Sandulache V, Sikora AG. Human epidermal growth factor receptor 2 expression in head and neck squamous cell carcinoma: Variation within and across primary tumor sites, and implications for antigen-specific immunotherapy. Head Neck. 2021 07; 43(7):1983-1994. PMID: 33660372.
      Citations: 1     Fields:    Translation:Humans
    6. McKenna MK, Englisch A, Brenner B, Smith T, Hoyos V, Suzuki M, Brenner MK. Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity. Mol Ther. 2021 05 05; 29(5):1808-1820. PMID: 33571680.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    7. Tremblay JP, Annoni A, Suzuki M. Three Decades of Clinical Gene Therapy: From Experimental Technologies to Viable Treatments. Mol Ther. 2021 02 03; 29(2):411-412. PMID: 33472032.
      Citations: 1     Fields:    Translation:Humans
    8. Watanabe N, McKenna MK, Rosewell Shaw A, Suzuki M. Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment. Mol Ther. 2021 02 03; 29(2):505-520. PMID: 33130314.
      Citations: 8     Fields:    Translation:HumansCells
    9. Cao F, Nguyen P, Hong B, DeRenzo C, Rainusso NC, Rodriguez Cruz T, Wu MF, Liu H, Song XT, Suzuki M, Wang LL, Yustein JT, Gottschalk S. Engineering Oncolytic Vaccinia Virus to redirect Macrophages to Tumor Cells. Adv Cell Gene Ther. 2021 Apr; 4(2). PMID: 33829146.
      Citations: 2     
    10. McKenna MK, Rosewell-Shaw A, Suzuki M. Modeling the Efficacy of Oncolytic Adenoviruses In Vitro and In Vivo: Current and Future Perspectives. Cancers (Basel). 2020 Mar 07; 12(3). PMID: 32155969.
      Citations: 4     
    11. Porter CE, Rosewell Shaw A, Jung Y, Yip T, Castro PD, Sandulache VC, Sikora A, Gottschalk S, Ittman MM, Brenner MK, Suzuki M. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors. Mol Ther. 2020 05 06; 28(5):1251-1262. PMID: 32145203.
      Citations: 47     Fields:    Translation:HumansAnimalsCells
    12. Shaw AR, Suzuki M. Immunology of Adenoviral Vectors in Cancer Therapy. Mol Ther Methods Clin Dev. 2019 Dec 13; 15:418-429. PMID: 31890734.
      Citations: 28     
    13. Rosewell Shaw A, Suzuki M. Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment. Front Immunol. 2018; 9:2103. PMID: 30298067.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    14. Rosewell Shaw A, Porter CE, Watanabe N, Tanoue K, Sikora A, Gottschalk S, Brenner MK, Suzuki M. Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer. Mol Ther. 2017 11 01; 25(11):2440-2451. PMID: 28974431.
      Citations: 77     Fields:    Translation:HumansAnimalsCells
    15. Suzuki M. Partners in Crime: Combining Oncolytic Viroimmunotherapy with Other Therapies. Mol Ther. 2017 04 05; 25(4):836-838. PMID: 28330695.
      Citations: 2     Fields:    Translation:HumansCells
    16. Tanoue K, Rosewell Shaw A, Watanabe N, Porter C, Rana B, Gottschalk S, Brenner M, Suzuki M. Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Res. 2017 04 15; 77(8):2040-2051. PMID: 28235763.
      Citations: 97     Fields:    Translation:HumansAnimalsCells
    17. Otsuki A, Patel A, Kasai K, Suzuki M, Kurozumi K, Antonio Chiocca E, Saeki Y. Histone Deacetylase Inhibitors Augment Antitumor Efficacy of Herpes-based Oncolytic Viruses. Mol Ther. 2008 Sep; 16(9):1546-1555. PMID: 28189010.
      Citations: 5     Fields:    
    18. Rosewell Shaw A, Suzuki M. Recent advances in oncolytic adenovirus therapies for cancer. Curr Opin Virol. 2016 12; 21:9-15. PMID: 27379906.
      Citations: 52     Fields:    Translation:Cells
    19. Rajagopal A, Homan EP, Joeng KS, Suzuki M, Bertin T, Cela R, Munivez E, Dawson B, Jiang MM, Gannon F, Crawford S, Lee BH. Restoration of the serum level of SERPINF1 does not correct the bone phenotype in Serpinf1 null mice. Mol Genet Metab. 2016 Mar; 117(3):378-82. PMID: 26693895.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    20. Hoyos V, Del Bufalo F, Yagyu S, Ando M, Dotti G, Suzuki M, Bouchier-Hayes L, Alemany R, Brenner MK. Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers. Mol Ther. 2015 Sep; 23(9):1497-506. PMID: 26084970.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    21. Rogers GL, Suzuki M, Zolotukhin I, Markusic DM, Morel LM, Lee B, Ertl HC, Herzog RW. Unique Roles of TLR9- and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene Transfer. J Innate Immun. 2015; 7(3):302-14. PMID: 25612611.
      Citations: 30     Fields:    Translation:AnimalsCells
    22. Farzad L, Cerullo V, Yagyu S, Bertin T, Hemminki A, Rooney C, Lee B, Suzuki M. Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy. Mol Ther Oncolytics. 2014; 1:14008. PMID: 27119096.
      Citations: 15     
    23. Farzad LM, Suzuki M. Feasibility of Applying Helper-Dependent Adenoviral Vectors for Cancer Immunotherapy. Biomedicines. 2014 Mar 10; 2(1):110-131. PMID: 28548063.
      Citations: 3     
    24. Suzuki M, Bertin TK, Rogers GL, Cela RG, Zolotukhin I, Palmer DJ, Ng P, Herzog RW, Lee B. Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo. Mol Ther. 2013 Apr; 21(4):796-805. PMID: 23319058.
      Citations: 31     Fields:    Translation:AnimalsCells
    25. Suzuki M, Rooney CM. Adenovirus immunity: X marks the spot. Mol Ther. 2012 Dec; 20(12):2197-8. PMID: 23201614.
      Citations: 1     Fields:    Translation:HumansCells
    26. Guse K, Suzuki M, Sule G, Bertin TK, Tyynismaa H, Ahola-Erkkilä S, Palmer D, Suomalainen A, Ng P, Cerullo V, Hemminki A, Lee B. Capsid-modified adenoviral vectors for improved muscle-directed gene therapy. Hum Gene Ther. 2012 Oct; 23(10):1065-70. PMID: 22888960.
      Citations: 15     Fields:    Translation:AnimalsCells
    27. Sule G, Suzuki M, Guse K, Cela R, Rodgers JR, Lee B. Cytokine-conditioned dendritic cells induce humoral tolerance to protein therapy in mice. Hum Gene Ther. 2012 Jul; 23(7):769-80. PMID: 22468961.
      Citations: 5     Fields:    Translation:AnimalsCells
    28. Suzuki M, Cela R, Bertin TK, Sule G, Cerullo V, Rodgers JR, Lee B. NOD2 signaling contributes to the innate immune response against helper-dependent adenovirus vectors independently of MyD88 in vivo. Hum Gene Ther. 2011 Sep; 22(9):1071-82. PMID: 21561248.
      Citations: 14     Fields:    Translation:AnimalsCells
    29. Martino AT, Suzuki M, Markusic DM, Zolotukhin I, Ryals RC, Moghimi B, Ertl HC, Muruve DA, Lee B, Herzog RW. The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood. 2011 Jun 16; 117(24):6459-68. PMID: 21474674.
      Citations: 114     Fields:    Translation:AnimalsCells
    30. Hu C, Cela RG, Suzuki M, Lee B, Lipshutz GS. Neonatal helper-dependent adenoviral vector gene therapy mediates correction of hemophilia A and tolerance to human factor VIII. Proc Natl Acad Sci U S A. 2011 Feb 01; 108(5):2082-7. PMID: 21245323.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    31. Suzuki M, Cerullo V, Bertin TK, Cela R, Clarke C, Guenther M, Brunetti-Pierri N, Lee B. MyD88-dependent silencing of transgene expression during the innate and adaptive immune response to helper-dependent adenovirus. Hum Gene Ther. 2010 Mar; 21(3):325-36. PMID: 19824822.
      Citations: 20     Fields:    Translation:AnimalsCells
    32. Suzuki M, Cela R, Clarke C, Bertin TK, Mouriño S, Lee B. Large-scale production of high-quality helper-dependent adenoviral vectors using adherent cells in cell factories. Hum Gene Ther. 2010 Jan; 21(1):120-6. PMID: 19719388.
      Citations: 26     Fields:    Translation:HumansCells
    33. Suzuki M, Kasai K, Ohtsuki A, Godlewski J, Nowicki MO, Chiocca EA, Saeki Y. ICP0 inhibits the decrease of HSV amplicon-mediated transgene expression. Mol Ther. 2009 Apr; 17(4):707-15. PMID: 19223864.
      Citations: 4     Fields:    Translation:AnimalsCells
    34. Suzuki M, Chiocca EA, Saeki Y. Stable transgene expression from HSV amplicon vectors in the brain: potential involvement of immunoregulatory signals. Mol Ther. 2008 Oct; 16(10):1727-36. PMID: 18728642.
      Citations: 10     Fields:    Translation:AnimalsCells
    35. Otsuki A, Patel A, Kasai K, Suzuki M, Kurozumi K, Chiocca EA, Saeki Y. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther. 2008 Sep; 16(9):1546-55. PMID: 18648350.
      Citations: 80     Fields:    Translation:HumansAnimalsCells
    36. Suzuki M, Chiocca EA, Saeki Y. Early STAT1 activation after systemic delivery of HSV amplicon vectors suppresses transcription of the vector-encoded transgene. Mol Ther. 2007 Nov; 15(11):2017-26. PMID: 17653098.
      Citations: 14     Fields:    Translation:AnimalsCells
    37. Suzuki M, Kasai K, Saeki Y. Plasmid DNA sequences present in conventional herpes simplex virus amplicon vectors cause rapid transgene silencing by forming inactive chromatin. J Virol. 2006 Apr; 80(7):3293-300. PMID: 16537596.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    38. Suzuki M, Takayanagi A, Shimizu N. Targeted gene delivery using humanized single-chain antibody with negatively charged oligopeptide tail. Cancer Sci. 2004 May; 95(5):424-9. PMID: 15132770.
      Citations: 2     Fields:    Translation:HumansCells
    SUZUKI's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (190)
    Explore
    _
    Co-Authors (21)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _